FROM MULTIPLE MYELOMA TO GAUCHER DISEASE Webinar FROM MULTIPLE MYELOMA TO GAUCHER DISEASE SETTING THE NEW STANDARDS 01.10 18h30 QUINTA-FEIRA Nome* Pergunta* FROM MULTIPLE MYELOMA TO GAUCHER DISEASE × 1. Your choice for therapy of RRMM patients is often driven by: Data from RCTs Real-world evidence data Patient choice Fitness and comorbidities 2. How important do you think RWE is in current clinical pratice? Very important. They may have an influence on my clinical pratice Important but will not influence my clinical pratice Relative important / interesting Not important Vote WELCOME KEYNOTE SPEAKERS @master2020-10-07T18:44:22+01:00